Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency
Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules
The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation
Honan will lead the company in identifying and executing acquisitions that complement Emmes’ existing strong federal government client base, expand its biopharma portfolio, enhance its technology offerings, and broaden its global reach
Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations
The unit will have installed manufacturing capacity of over 15 million vials annually that includes lyophilized vials, all in the anti-cancer segment
The strategic acquirer maintains a nationwide presence in the LTC pharmacy space
The proposed initiative is conceptualised with an objective to identify, support, and promote innovative research ideas in healthcare research
Passengers arriving from 6 high-risk countries are now mandatorily required to upload their negative RT-PCR test
Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.
Subscribe To Our Newsletter & Stay Updated
